Department of Pathology, Seoul National University Hospital, Seoul, Korea.
Am J Surg Pathol. 2010 May;34(5):645-55. doi: 10.1097/PAS.0b013e3181d5d903.
Class III beta-tubulin (TUBB3) expression in carcinoma is associated with resistance to tubulin-binding chemotherapeutic agents. Recently, follicular dendritic cells (FDCs) were reported to express TUBB3 under physiologic conditions. We investigated TUBB3 expression in a wide range of lymphoproliferative disorders using immunohistochemistry. Dual immunostaining for Bcl-6 and TUBB3 revealed that some germinal center B cells also express TUBB3 in addition to FDCs. In Hodgkin lymphomas (HLs), 47.1% (40/85) expressed TUBB3 in the tumor cells with an all-or-none pattern. TUBB3 expression in HL was more common in mixed cellularity type than nodular sclerosis type (P=0.032). Among non-HLs, 79.3% (23/29) of anaplastic large cell lymphoma (ALCL), 8% (2/25) of extranodal natural killer/T-cell lymphoma, and 75% (21/28) of Burkitt lymphoma showed TUBB3 expression with an all-or-none pattern. Of diffuse large B-cell lymphoma, 15.2% (32/210) expressed TUBB3 in a heterogeneous pattern. In ALCL, TUBB3 expression was more common in systemic ALCL than in primary cutaneous ALCL (P=0.046). Diffuse large B-cell lymphomas with a germinal center B-like subgroup exhibited TUBB3 expression more frequently than non-GCB-like subgroup (P=0.01). Otherwise, none of the 18 angioimmunoblastic T-cell lymphomas; 18 peripheral T-cell lymphomas, not otherwise specified; 12 follicular lymphomas; 62 marginal zone lymphomas; 7 mantle cell lymphomas; 8 small lymphocytic lymphomas; or 2 FDC sarcomas expressed TUBB3. In angioimmunoblastic T-cell lymphoma and Castleman disease, TUBB3 was positive in immunoblasts corresponding to Epstein-Barr virus-infected or Kaposi sarcoma herpes virus-infected cells. A variety of neoplastic and non-neoplastic lymphoproliferative disorders exhibited characteristic TUBB3 expression patterns; these results suggest potential for diagnostic utility, some insight into the pathobiology of TUBB3 expression, and potential therapeutic implications.
III 类β-微管蛋白（TUBB3）在癌中的表达与微管结合化疗药物的耐药性有关。最近，有报道称滤泡树突状细胞（FDC）在生理条件下表达 TUBB3。我们使用免疫组织化学方法研究了广泛的淋巴增生性疾病中的 TUBB3 表达。Bcl-6 和 TUBB3 的双重免疫染色显示，除了 FDC 之外，一些生发中心 B 细胞也表达 TUBB3。在霍奇金淋巴瘤（HL）中，47.1%（40/85）的肿瘤细胞呈全或无模式表达 TUBB3。混合细胞性 HL 比结节性硬化性 HL 更常见 TUBB3 表达（P=0.032）。在非霍奇金淋巴瘤中，79.3%（23/29）的间变大细胞淋巴瘤（ALCL）、8%（2/25）的结外自然杀伤/T 细胞淋巴瘤和 75%（21/28）的伯基特淋巴瘤呈全或无模式表达 TUBB3。弥漫性大 B 细胞淋巴瘤中，15.2%（32/210）呈异质性表达 TUBB3。在 ALCL 中，系统性 ALCL 比原发性皮肤 ALCL 更常见 TUBB3 表达（P=0.046）。生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤比非 GCB 样弥漫性大 B 细胞淋巴瘤更常表达 TUBB3（P=0.01）。其他 18 例血管免疫母细胞性 T 细胞淋巴瘤、18 例外周 T 细胞淋巴瘤、12 例滤泡性淋巴瘤、62 例边缘区淋巴瘤、7 例套细胞淋巴瘤、8 例小淋巴细胞淋巴瘤或 2 例滤泡树突状肉瘤均不表达 TUBB3。在血管免疫母细胞性 T 细胞淋巴瘤和 Castleman 病中，TUBB3 在对应于 EBV 感染或卡波西肉瘤疱疹病毒感染细胞的免疫母细胞中呈阳性。多种肿瘤性和非肿瘤性淋巴增生性疾病表现出特征性的 TUBB3 表达模式；这些结果表明具有潜在的诊断效用，对 TUBB3 表达的病理生物学有一些了解，以及潜在的治疗意义。
